Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fu-Shun Yen

Showing results (71-80 of 101) with videos related to

Pageof 11
Sort By:
BMC Endocrine Disorders|January 7, 2019
All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetesFu-Shun Yen, Jen-Huai Chiang, Chii-Min Hwu, et al.
Frontiers in Pharmacology|January 9, 2023
Liver-related long-term outcomes of alpha-glucosidase inhibitors in patients with diabetes and liver cirrhosisFu-Shun Yen, Ming-Chih Hou, James Cheng-Chung Wei, et al.
Plos One|December 14, 2020
Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosisFu-Shun Yen, Jung-Nien Lai, James Cheng-Chung Wei, et al.
Journal of Internal Medicine|February 25, 2025
Effects of SGLT2 inhibitors on transplant survival and key clinical outcomes in heart transplant recipients with diabetesFu-Shun Yen, Yao-Min Hung, Jing-Yang Huang, et al.
Journal of Diabetes Investigation|November 14, 2024
Impact of family income on the development of gestational diabetes mellitus and the associated birth outcomes: A nationwide studyFu-Shun Yen, James Cheng-Chung Wei, Yi-Ling Wu, et al.
Diabetes & Metabolic Syndrome|August 11, 2024
Glucagon-like peptide-1 receptor agonists and risk of sight-threatening retinopathy in Taiwanese population: A propensity based cohort studyFu-Shun Yen, James Cheng-Chung Wei, Ying-Hsiu Shih, et al.
Journal of Human Hypertension|May 6, 2020
Urate-lowering therapy exerts protective effects against hypertension development in patients with goutKuan-Hung Lin, Fu-Shun Yen, Hsin-Lun Li, et al.
BMC Gastroenterology|June 13, 2021
Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?Fu-Shun Yen, Jung-Nien Lai, James Cheng-Chung Wei, et al.
International Journal of Environmental Research and Public Health|September 9, 2022
Metformin and the Risk of Chronic Urticaria in Patients with Type 2 DiabetesFu-Shun Yen, Chih-Cheng Hsu, Kai-Chieh Hu, et al.
Journal of the Chinese Medical Association : JCMA|February 28, 2024
Metformin and the risks of cellulitis, foot infections, and amputation in patients with type 2 diabetesYun-Kai Yeh, Fu-Shun Yen, James Cheng-Chung Wei, et al.
Pageof 11

Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
BMC Endocrine Disorders|January 7, 2019
All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetesFu-Shun Yen, Jen-Huai Chiang, Chii-Min Hwu, et al.
Frontiers in Pharmacology|January 9, 2023
Liver-related long-term outcomes of alpha-glucosidase inhibitors in patients with diabetes and liver cirrhosisFu-Shun Yen, Ming-Chih Hou, James Cheng-Chung Wei, et al.
Plos One|December 14, 2020
Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosisFu-Shun Yen, Jung-Nien Lai, James Cheng-Chung Wei, et al.
Journal of Internal Medicine|February 25, 2025
Effects of SGLT2 inhibitors on transplant survival and key clinical outcomes in heart transplant recipients with diabetesFu-Shun Yen, Yao-Min Hung, Jing-Yang Huang, et al.
Journal of Diabetes Investigation|November 14, 2024
Impact of family income on the development of gestational diabetes mellitus and the associated birth outcomes: A nationwide studyFu-Shun Yen, James Cheng-Chung Wei, Yi-Ling Wu, et al.
Diabetes & Metabolic Syndrome|August 11, 2024
Glucagon-like peptide-1 receptor agonists and risk of sight-threatening retinopathy in Taiwanese population: A propensity based cohort studyFu-Shun Yen, James Cheng-Chung Wei, Ying-Hsiu Shih, et al.
Journal of Human Hypertension|May 6, 2020
Urate-lowering therapy exerts protective effects against hypertension development in patients with goutKuan-Hung Lin, Fu-Shun Yen, Hsin-Lun Li, et al.
BMC Gastroenterology|June 13, 2021
Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?Fu-Shun Yen, Jung-Nien Lai, James Cheng-Chung Wei, et al.
International Journal of Environmental Research and Public Health|September 9, 2022
Metformin and the Risk of Chronic Urticaria in Patients with Type 2 DiabetesFu-Shun Yen, Chih-Cheng Hsu, Kai-Chieh Hu, et al.
Journal of the Chinese Medical Association : JCMA|February 28, 2024
Metformin and the risks of cellulitis, foot infections, and amputation in patients with type 2 diabetesYun-Kai Yeh, Fu-Shun Yen, James Cheng-Chung Wei, et al.
Pageof 11